{
    "id": 5295,
    "date": "2026-10-30T09:49:51",
    "date_gmt": "2026-10-30T08:49:51",
    "guid": {
        "rendered": "https:\/\/www.phinc-group.com\/?p=5295"
    },
    "modified": "2026-11-02T11:08:57",
    "modified_gmt": "2026-11-02T10:08:57",
    "slug": "midd-for-rare-diseases-therapies",
    "status": "publish",
    "type": "post",
    "link": "https:\/\/www.phinc-group.com\/fr\/midd-for-rare-diseases-therapies\/",
    "title": {
        "rendered": "Le r\u00f4le du MIDD dans le d\u00e9veloppement de m\u00e9dicaments pour les maladies rares\u00a0"
    },
    "content": {
        "rendered": "<div data-elementor-type=\"wp-post\" data-elementor-id=\"5295\" class=\"elementor elementor-5295\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-610da39 e-con-full e-flex e-con e-parent\" data-id=\"610da39\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2bdb7b8 elementor-widget elementor-widget-html\" data-id=\"2bdb7b8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"mrd-page\">\r\n<style>\r\n@import url('https:\/\/fonts.googleapis.com\/css2?family=Cormorant+Garamond:ital,wght@0,300;0,500;1,300&family=Poppins:wght@200;300;400;600;700&display=swap');\r\n\r\n.mrd-page{\r\n  --phinc-blue:#00005f;\r\n  --phinc-pink:#d94b9f;\r\n  --ink:#0F172A;\r\n  --muted:#475569;\r\n  --line:#E6EAF2;\r\n  --bg:#F7F9FC;\r\n  --card:#FFFFFF;\r\n  --radius:18px;\r\n  --shadow: 0 10px 30px rgba(15,23,42,.08);\r\n  background:var(--bg);\r\n  color:var(--ink);\r\n  font-family:'Poppins',Arial,sans-serif;\r\n  -webkit-font-smoothing:antialiased;\r\n}\r\n.mrd-page *{box-sizing:border-box;}\r\n.mrd-page em{font-style:normal;color:var(--phinc-pink);}\r\n.mrd-page .mrd-container{max-width:1080px;margin:0 auto;padding:0 32px;}\r\n\r\n\/* ---------- HERO CENTR\u00c9 ---------- *\/\r\n.mrd-hero{padding:88px 0 40px;text-align:center;}\r\n.mrd-eyebrow{\r\n  display:inline-flex;align-items:center;gap:8px;\r\n  padding:8px 18px;border-radius:999px;\r\n  background:linear-gradient(135deg, rgba(0,0,95,.06), rgba(217,75,159,.10));\r\n  border:1px solid var(--line);\r\n  font-family:'Poppins',sans-serif;font-weight:600;font-size:12px;\r\n  letter-spacing:.14em;text-transform:uppercase;color:var(--phinc-blue);\r\n  margin-bottom:28px;\r\n}\r\n.mrd-eyebrow .mrd-dot{\r\n  width:8px;height:8px;border-radius:50%;\r\n  background:linear-gradient(135deg, var(--phinc-blue), var(--phinc-pink));\r\n  display:inline-block;\r\n}\r\n.mrd-hero h1{\r\n  font-family:'Cormorant Garamond',serif;font-weight:300;\r\n  font-size:52px;line-height:1.12;color:var(--phinc-blue);\r\n  margin:0 auto 24px;max-width:780px;text-wrap:balance;\r\n}\r\n.mrd-hero .mrd-standfirst{\r\n  font-family:'Poppins',sans-serif;font-weight:200;font-size:17px;\r\n  line-height:1.8;color:var(--muted);max-width:720px;margin:0 auto 28px;text-wrap:balance;\r\n}\r\n.mrd-meta-row{display:flex;flex-wrap:wrap;gap:10px;justify-content:center;}\r\n.mrd-meta-pill{\r\n  padding:7px 16px;border-radius:999px;border:1px solid var(--line);\r\n  background:#fff;font-size:13px;font-weight:600;color:var(--phinc-blue);\r\n}\r\n\r\n\/* ---------- VISUELS ---------- *\/\r\n.mrd-visual{\r\n  width:100%;border-radius:var(--radius);overflow:hidden;\r\n  border:1px solid var(--line);box-shadow:var(--shadow);\r\n  background:linear-gradient(135deg, rgba(0,0,95,.06), rgba(217,75,159,.08));\r\n}\r\n.mrd-visual{position:relative;}\r\n.mrd-visual img{display:block;width:100%;height:100%;object-fit:cover;}\r\n.mrd-ai-credit{\r\n  position:absolute;right:12px;bottom:10px;\r\n  font-family:'Poppins',sans-serif;font-weight:400;font-size:10.5px;\r\n  letter-spacing:.04em;color:rgba(255,255,255,.88);\r\n  background:rgba(15,23,42,.38);backdrop-filter:blur(4px);\r\n  padding:4px 10px;border-radius:999px;line-height:1.3;\r\n  pointer-events:none;\r\n}\r\n.mrd-visual.banner{aspect-ratio:21\/7;margin:16px 0 8px;}\r\n.mrd-visual.wide{aspect-ratio:16\/9;margin:40px 0;}\r\n\/* ---------- DIVIDER ---------- *\/\r\n.mrd-divider{border:none;border-top:1px solid var(--line);margin:8px 0 56px;}\r\n\r\n\/* ---------- SECTIONS ---------- *\/\r\n.mrd-section{padding:8px 0 56px;}\r\n.mrd-kicker{\r\n  display:block;font-family:'Poppins',sans-serif;font-weight:700;\r\n  font-size:12px;letter-spacing:.14em;text-transform:uppercase;\r\n  color:var(--phinc-pink);margin-bottom:14px;\r\n}\r\n.mrd-section h2{\r\n  font-family:'Cormorant Garamond',serif;font-weight:300;font-size:38px;\r\n  color:var(--phinc-blue);margin:0 0 28px;max-width:900px;\r\n}\r\n.mrd-section h3{\r\n  font-family:'Poppins',sans-serif;font-weight:600;font-size:19px;\r\n  color:var(--ink);margin:0 0 10px;\r\n}\r\n.mrd-section p{\r\n  font-family:'Poppins',sans-serif;font-weight:300;font-size:16px;\r\n  line-height:1.85;color:var(--muted);margin:0 0 18px;\r\n}\r\n.mrd-section strong{font-weight:600;color:var(--ink);}\r\n.mrd-section sup{font-size:11px;font-weight:600;color:var(--phinc-pink);}\r\n\r\n\/* ---------- COMPARAISON AVANT \/ APR\u00c8S ---------- *\/\r\n.mrd-compare{display:grid;grid-template-columns:1fr 1fr;gap:24px;margin:36px 0;}\r\n.mrd-compare > div{\r\n  background:var(--card);border:1px solid var(--line);border-left:3px solid var(--line-strong, #C7CEDE);\r\n  border-radius:var(--radius);box-shadow:var(--shadow);padding:30px 32px;\r\n}\r\n.mrd-compare > div.mrd-now{border-left-color:var(--phinc-pink);}\r\n.mrd-compare-label{\r\n  font-family:'Poppins',sans-serif;font-weight:700;font-size:11.5px;\r\n  letter-spacing:.14em;text-transform:uppercase;color:var(--muted);margin:0 0 12px;\r\n}\r\n.mrd-compare .mrd-now .mrd-compare-label{color:var(--phinc-pink);}\r\n.mrd-compare p:last-child{margin-bottom:0;}\r\n\r\n\/* ---------- APPLICATIONS : LISTE NUM\u00c9ROT\u00c9E ---------- *\/\r\n.mrd-apps{margin:40px 0 0;}\r\n.mrd-app{\r\n  display:grid;grid-template-columns:96px minmax(0,1fr);gap:28px;\r\n  padding:34px 0;border-top:1px solid var(--line);\r\n}\r\n.mrd-app:last-child{border-bottom:1px solid var(--line);}\r\n.mrd-app-num{\r\n  font-family:'Cormorant Garamond',serif;font-weight:300;font-size:56px;line-height:1;\r\n  color:var(--phinc-pink);\r\n}\r\n.mrd-app-tag{\r\n  font-family:'Poppins',sans-serif;font-weight:600;font-size:11.5px;\r\n  letter-spacing:.12em;text-transform:uppercase;color:var(--phinc-blue);\r\n  background:var(--bg);border:1px solid var(--line);\r\n  padding:4px 10px;border-radius:999px;display:inline-block;margin-top:14px;\r\n}\r\n.mrd-app p:last-of-type{margin-bottom:0;}\r\n\r\n\/* ---------- PULL QUOTE ---------- *\/\r\n.mrd-quote{\r\n  position:relative;overflow:hidden;\r\n  background:linear-gradient(135deg, rgba(0,0,95,.05), rgba(217,75,159,.08));\r\n  border:1px solid var(--line);border-radius:var(--radius);\r\n  padding:48px 56px;margin:48px 0;\r\n}\r\n.mrd-section > .mrd-quote:last-child{margin-bottom:0;}\r\n.mrd-quote .mrd-quote-mark{\r\n  position:absolute;top:-30px;left:16px;\r\n  font-family:'Cormorant Garamond',serif;font-size:180px;\r\n  color:var(--phinc-pink);opacity:.12;line-height:1;\r\n}\r\n.mrd-quote p{\r\n  position:relative;font-family:'Cormorant Garamond',serif;font-style:italic;\r\n  font-weight:300;font-size:22px;line-height:1.6;color:var(--phinc-blue);margin:0;\r\n}\r\n\r\n\/* ---------- PRATIQUES ---------- *\/\r\n.mrd-practices{display:grid;grid-template-columns:1fr 1fr;gap:24px;margin:36px 0 0;}\r\n.mrd-practice{\r\n  background:var(--card);border:1px solid var(--line);border-radius:var(--radius);\r\n  box-shadow:var(--shadow);padding:32px 30px;\r\n}\r\n.mrd-icon-chip{\r\n  width:48px;height:48px;border-radius:12px;margin-bottom:20px;\r\n  display:flex;align-items:center;justify-content:center;font-size:22px;\r\n  background:linear-gradient(135deg, rgba(0,0,95,.10), rgba(217,75,159,.14));\r\n  color:var(--phinc-blue);\r\n}\r\n.mrd-practice p:last-child{margin-bottom:0;font-size:15px;}\r\n\r\n\/* ---------- R\u00c9F\u00c9RENCES ---------- *\/\r\n.mrd-refs{\r\n  background:var(--card);border:1px solid var(--line);border-radius:var(--radius);\r\n  padding:32px 36px;margin-top:20px;\r\n}\r\n.mrd-refs ol{margin:0;padding-left:20px;}\r\n.mrd-refs li{\r\n  font-family:'Poppins',sans-serif;font-weight:300;font-size:13.5px;\r\n  color:var(--muted);line-height:1.8;margin-bottom:10px;\r\n}\r\n.mrd-refs em{font-style:italic;}\r\n.mrd-refs a{color:var(--phinc-blue);text-decoration:none;word-break:break-all;}\r\n.mrd-refs a:hover{text-decoration:underline;}\r\n\r\n\/* ---------- CTA SUR VISUEL ---------- *\/\r\n.mrd-cta{\r\n  position:relative;overflow:hidden;border-radius:var(--radius);\r\n  background-color:var(--phinc-blue);\r\n  background-size:cover;background-position:center;\r\n  min-height:440px;\r\n  display:flex;flex-direction:column;align-items:center;justify-content:center;\r\n  padding:88px 56px;text-align:center;margin:24px 0 96px;\r\n}\r\n.mrd-cta::before{\r\n  content:\"\";position:absolute;inset:0;\r\n  background:linear-gradient(135deg, rgba(0,0,95,.86) 0%, rgba(0,0,95,.60) 55%, rgba(74,21,96,.55) 100%);\r\n}\r\n.mrd-cta::after{\r\n  content:\"\";position:absolute;top:-140px;right:-110px;width:360px;height:360px;\r\n  border-radius:50%;background:radial-gradient(circle, rgba(217,75,159,.45), transparent 70%);\r\n}\r\n.mrd-cta h2{\r\n  position:relative;font-family:'Cormorant Garamond',serif;font-weight:300;\r\n  font-size:42px;color:#fff;margin:0 0 18px;max-width:760px;\r\n  text-shadow:0 2px 24px rgba(0,0,40,.45);\r\n}\r\n.mrd-cta h2 em{color:#f9b8e4;}\r\n.mrd-cta p{\r\n  position:relative;font-family:'Poppins',sans-serif;font-weight:300;font-size:16px;\r\n  color:rgba(255,255,255,.92);max-width:620px;margin:0 auto 36px;line-height:1.7;\r\n  text-shadow:0 1px 16px rgba(0,0,40,.45);\r\n}\r\n.mrd-cta-buttons{position:relative;display:flex;gap:16px;justify-content:center;flex-wrap:wrap;}\r\n.mrd-btn{\r\n  font-family:'Poppins',sans-serif;font-weight:600;font-size:14.5px;\r\n  padding:14px 30px;border-radius:12px;text-decoration:none;display:inline-block;\r\n}\r\n.mrd-btn.primary{background:var(--phinc-pink);color:#fff;box-shadow:0 8px 20px rgba(217,75,159,.4);}\r\n.mrd-btn.ghost{\r\n  background:rgba(255,255,255,.12);color:#fff;\r\n  border:1px solid rgba(255,255,255,.6);backdrop-filter:blur(6px);\r\n}\r\n\r\n@media (max-width:980px){\r\n  .mrd-compare{grid-template-columns:1fr;}\r\n  .mrd-practices{grid-template-columns:1fr;}\r\n}\r\n@media (max-width:860px){\r\n  .mrd-hero{padding:64px 0 32px;}\r\n  .mrd-hero h1{font-size:34px;}\r\n  .mrd-hero .mrd-standfirst{font-size:15px;}\r\n  .mrd-visual.banner{aspect-ratio:16\/9;}\r\n  .mrd-app{grid-template-columns:1fr;gap:10px;}\r\n  .mrd-app-num{font-size:40px;}\r\n  .mrd-quote{padding:36px 28px;}\r\n  .mrd-cta{padding:56px 28px;min-height:360px;}\r\n}\r\n<\/style>\r\n\r\n<div class=\"mrd-container\">\r\n\r\n  <!-- HERO -->\r\n  <section class=\"mrd-hero\">\r\n    <span class=\"mrd-eyebrow\"><span class=\"mrd-dot\"><\/span>MIDD &amp; Maladies rares<\/span>\r\n    <h1>Le r\u00f4le du MIDD dans le d\u00e9veloppement de m\u00e9dicaments pour les <em>maladies rares<\/em><\/h1>\r\n    <p class=\"mrd-standfirst\">Dans tout programme clinique sur les maladies rares, il arrive un stade o\u00f9 les cadres statistiques traditionnels se heurtent \u00e0 de profondes limites.<\/p>\r\n    <div class=\"mrd-meta-row\">\r\n      <span class=\"mrd-meta-pill\">ICH M15 \u00b7 ICH E11A<\/span>\r\n      <span class=\"mrd-meta-pill\">PopPK \u00b7 QSP \u00b7 PK\/PD<\/span>\r\n      <span class=\"mrd-meta-pill\">Extrapolation p\u00e9diatrique<\/span>\r\n    <\/div>\r\n  <\/section>\r\n\r\n  <!-- VISUEL IMG-01 -->\r\n  <figure class=\"mrd-visual banner\">\r\n    <img fetchpriority=\"high\" decoding=\"async\" src=\"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/10\/Analyste-en-biotechnologie-au-travail.png\"\r\n         alt=\"Analyste en biotechnologie travaillant sur une visualisation de mod\u00e8le humain et de donn\u00e9es\"\r\n         width=\"2400\" height=\"800\">\r\n    <span class=\"mrd-ai-credit\">Image g\u00e9n\u00e9r\u00e9e par IA<\/span>\r\n  <\/figure>\r\n\r\n  <section class=\"mrd-section\" style=\"padding-top:40px;\">\r\n    <p>\u00c0 ce moment charni\u00e8re, le d\u00e9veloppement de m\u00e9dicaments inform\u00e9 par la mod\u00e9lisation (MIDD) n'est plus une option exploratoire, mais devient <strong>une strat\u00e9gie de survie critique<\/strong>. Le MIDD permet de transformer des signaux cliniques parsem\u00e9s en une feuille de route d\u00e9finitive et m\u00e9canistiquement solide en vue d'une approbation r\u00e9glementaire.<\/p>\r\n  <\/section>\r\n\r\n  <hr class=\"mrd-divider\">\r\n\r\n  <!-- SECTION 1 -->\r\n  <section class=\"mrd-section\">\r\n    <span class=\"mrd-kicker\">Contexte<\/span>\r\n    <h2>Le changement de paradigme dans le d\u00e9veloppement des <em>maladies rares<\/em><\/h2>\r\n    <p>Le d\u00e9veloppement de m\u00e9dicaments dans les indications rares s'\u00e9loigne des essais empiriques standard \u00e0 grand volume au profit d'approches sur mesure et inform\u00e9es par la mod\u00e9lisation.<\/p>\r\n\r\n    <div class=\"mrd-compare\">\r\n      <div>\r\n        <p class=\"mrd-compare-label\">L'approche standard<\/p>\r\n        <p>Des essais empiriques \u00e0 grand volume, con\u00e7us pour une puissance statistique que la raret\u00e9 de la maladie rend hors d'atteinte.<\/p>\r\n      <\/div>\r\n      <div class=\"mrd-now\">\r\n        <p class=\"mrd-compare-label\">L'approche inform\u00e9e par la mod\u00e9lisation<\/p>\r\n        <p>Des programmes sur mesure, o\u00f9 la pharmacom\u00e9trie devient la force motrice des d\u00e9cisions de d\u00e9veloppement.<\/p>\r\n      <\/div>\r\n    <\/div>\r\n\r\n    <p>Les autorit\u00e9s sanitaires mondiales s'attendent de plus en plus \u00e0 ce que les promoteurs mettent en \u0153uvre les m\u00e9thodologies MIDD conform\u00e9ment aux directives telles que <strong>l'ICH M15<\/strong>, qui fournit un cadre devant \u00eatre rigoureusement suivi <sup>[3]<\/sup>. Les organismes de r\u00e9glementation exigent que la s\u00e9lection des doses et la conception des essais soient rigoureusement param\u00e9tr\u00e9es et scientifiquement transparentes.<\/p>\r\n  <\/section>\r\n\r\n  <hr class=\"mrd-divider\">\r\n\r\n  <!-- SECTION 2 -->\r\n  <section class=\"mrd-section\">\r\n    <span class=\"mrd-kicker\">Applications<\/span>\r\n    <h2>Quatre leviers de la <em>mod\u00e9lisation m\u00e9canistique<\/em><\/h2>\r\n    <p>Comprendre la r\u00e9ceptivit\u00e9 r\u00e9glementaire au MIDD permet aux promoteurs d'optimiser leurs cadres quantitatifs.<\/p>\r\n\r\n    <div class=\"mrd-apps\">\r\n\r\n      <div class=\"mrd-app\">\r\n        <span class=\"mrd-app-num\">01<\/span>\r\n        <div>\r\n          <h3>Pharmacocin\u00e9tique de population (PopPK)<\/h3>\r\n          <p>Dans les maladies rares, les donn\u00e9es cliniques sont par nature clairsem\u00e9es. La mod\u00e9lisation PopPK est essentielle pour extraire des informations d'exposition distinctes \u00e0 partir d'ensembles de donn\u00e9es limit\u00e9s et hautement variables. Les autorit\u00e9s s'attendent \u00e0 ce que ces mod\u00e8les s'ajustent aux covariables telles que le poids, l'\u00e2ge et la g\u00e9n\u00e9tique, garantissant un dosage optimal pour les sous-populations vuln\u00e9rables.<\/p>\r\n          <span class=\"mrd-app-tag\">Covariables \u00b7 Exposition<\/span>\r\n        <\/div>\r\n      <\/div>\r\n\r\n      <div class=\"mrd-app\">\r\n        <span class=\"mrd-app-num\">02<\/span>\r\n        <div>\r\n          <h3>Pharmacologie quantitative des syst\u00e8mes (QSP)<\/h3>\r\n          <p>Lorsque la biologie sous-jacente de la maladie est tr\u00e8s complexe et que les donn\u00e9es empiriques sont minces, la mod\u00e9lisation QSP \u00e9lucide les voies m\u00e9canistiques pour pr\u00e9dire l'efficacit\u00e9 th\u00e9rapeutique. Elle permet d'anticiper avec pr\u00e9cision les r\u00e9sultats cliniques avant m\u00eame un enr\u00f4lement massif de patients, en mod\u00e9lisant le syst\u00e8me biologique global ainsi que ses voies, ses boucles de r\u00e9troaction et les m\u00e9canismes de la maladie, tout en r\u00e9alisant des simulations m\u00e9dicamenteuses de mani\u00e8re m\u00e9canistique.<\/p>\r\n          <span class=\"mrd-app-tag\">Voies biologiques \u00b7 Simulation<\/span>\r\n        <\/div>\r\n      <\/div>\r\n\r\n      <div class=\"mrd-app\">\r\n        <span class=\"mrd-app-num\">03<\/span>\r\n        <div>\r\n          <h3>Int\u00e9gration PK\/PD<\/h3>\r\n          <p>La s\u00e9lection de la dose dans les maladies rares pr\u00e9sente des enjeux majeurs. Les simulations PK\/PD sont d\u00e9ploy\u00e9es pour d\u00e9finir rigoureusement la fen\u00eatre th\u00e9rapeutique avant la premi\u00e8re administration chez l'homme. Les \u00e9valuateurs exigent une cartographie math\u00e9matique exacte de la relation entre la concentration du m\u00e9dicament et la r\u00e9ponse biologique <sup>[2]<\/sup>.<\/p>\r\n          <p>Cette approche quantifie la mani\u00e8re dont l'exposition au m\u00e9dicament induit des effets biologiques ou cliniques, en reliant les profils concentration-temps \u00e0 la r\u00e9ponse par le biais de mod\u00e8les math\u00e9matiques <sup>[7]<\/sup>.<\/p>\r\n          <span class=\"mrd-app-tag\">Fen\u00eatre th\u00e9rapeutique \u00b7 FIH<\/span>\r\n        <\/div>\r\n      <\/div>\r\n\r\n      <div class=\"mrd-app\">\r\n        <span class=\"mrd-app-num\">04<\/span>\r\n        <div>\r\n          <h3>Extrapolation p\u00e9diatrique<\/h3>\r\n          <p>La mod\u00e9lisation p\u00e9diatrique est indispensable pour combler l'\u00e9cart d'efficacit\u00e9 entre l'adulte et l'enfant sans mener d'essais redondants \u00e0 faible puissance statistique. Des essais simul\u00e9s valident des sch\u00e9mas posologiques alternatifs, minimisant ainsi l'exposition des patients p\u00e9diatriques \u00e0 des cohortes exp\u00e9rimentales inutiles.<\/p>\r\n          <p>Elle est utilis\u00e9e lorsque la progression de la maladie et la r\u00e9ponse au traitement sont suffisamment similaires entre les adultes et les enfants, permettant aux donn\u00e9es adultes d'\u00e9clairer les d\u00e9cisions p\u00e9diatriques <sup>[4]<\/sup>. Elle contribue \u00e0 limiter les essais p\u00e9diatriques superflus tout en garantissant une posologie, une s\u00e9curit\u00e9 et une efficacit\u00e9 fond\u00e9es sur des preuves pour les enfants.<\/p>\r\n          <span class=\"mrd-app-tag\">ICH E11A \u00b7 Essais simul\u00e9s<\/span>\r\n        <\/div>\r\n      <\/div>\r\n\r\n    <\/div>\r\n\r\n    <!-- VISUEL IMG-02 -->\r\n    <figure class=\"mrd-visual wide\">\r\n      <img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/10\/Examen-medical-dans-une-clinique-de-campagne.png\"\r\n           alt=\"Examen m\u00e9dical d'un jeune enfant dans une clinique de campagne\"\r\n           width=\"1600\" height=\"900\">\r\n      <span class=\"mrd-ai-credit\">Image g\u00e9n\u00e9r\u00e9e par IA<\/span>\r\n    <\/figure>\r\n  <\/section>\r\n\r\n  <hr class=\"mrd-divider\">\r\n\r\n  <!-- SECTION 3 -->\r\n  <section class=\"mrd-section\">\r\n    <span class=\"mrd-kicker\">Meilleures pratiques<\/span>\r\n    <h2>Ce que les <em>promoteurs cliniques<\/em> doivent mettre en place<\/h2>\r\n    <p>Pour r\u00e9pondre avec succ\u00e8s aux attentes r\u00e9glementaires, les \u00e9quipes de pharmacologie clinique doivent adopter les pratiques suivantes :<\/p>\r\n\r\n    <div class=\"mrd-practices\">\r\n      <div class=\"mrd-practice\">\r\n        <div class=\"mrd-icon-chip\">\u25ce<\/div>\r\n        <h3>Engagement r\u00e9glementaire proactif<\/h3>\r\n        <p>Utilisez les interactions formelles avec les agences, telles que le programme de r\u00e9unions conjointes MIDD (MIDD Paired Meeting Program) de la FDA, pour obtenir un alignement pr\u00e9coce sur la strat\u00e9gie de mod\u00e9lisation propos\u00e9e et son application r\u00e9glementaire <sup>[5]<\/sup>.<\/p>\r\n      <\/div>\r\n      <div class=\"mrd-practice\">\r\n        <div class=\"mrd-icon-chip\">\u25c7<\/div>\r\n        <h3>Int\u00e9gration interfonctionnelle<\/h3>\r\n        <p>Une soumission MIDD solide requiert une collaboration harmonieuse entre les experts m\u00e9dicaux, les pharmacom\u00e9triciens et les biostatisticiens, afin de traduire les r\u00e9sultats math\u00e9matiques en informations cliniques exploitables et centr\u00e9es sur le patient.<\/p>\r\n      <\/div>\r\n    <\/div>\r\n  <\/section>\r\n\r\n  <hr class=\"mrd-divider\">\r\n\r\n  <!-- CONCLUSION -->\r\n  <section class=\"mrd-section\">\r\n    <span class=\"mrd-kicker\">Conclusion<\/span>\r\n    <h2>De l'exercice exploratoire \u00e0 l'<em>atout r\u00e9glementaire<\/em><\/h2>\r\n    <p>Alors que le d\u00e9veloppement de m\u00e9dicaments pour les maladies rares gagne en complexit\u00e9, le succ\u00e8s repose sur des mod\u00e8les pr\u00e9dictifs robustes. Le MIDD offre une voie scientifiquement rigoureuse pour r\u00e9duire les risques des essais cliniques et acc\u00e9l\u00e9rer la mise \u00e0 disposition de th\u00e9rapies salvatrices.<\/p>\r\n\r\n    <div class=\"mrd-quote\">\r\n      <span class=\"mrd-quote-mark\">&rdquo;<\/span>\r\n      <p>En privil\u00e9giant une validation PK\/PD exhaustive et en respectant les normes r\u00e9glementaires internationales, les promoteurs peuvent \u00e9lever la pharmacom\u00e9trie du rang d'exercice exploratoire \u00e0 celui d'atout r\u00e9glementaire d\u00e9cisif.<\/p>\r\n    <\/div>\r\n  <\/section>\r\n\r\n  <!-- CTA pos\u00e9 sur le visuel IMG-03 -->\r\n  <section class=\"mrd-cta\">\r\n    <!-- Remplacer par : style=\"background-image:url('URL-DU-VISUEL-IMG-03');\" -->\r\n    <h2>Faites du MIDD un <em>atout r\u00e9glementaire<\/em> pour votre programme<\/h2>\r\n    <p>L'\u00e9quipe PhinC accompagne les promoteurs en maladies rares : mod\u00e8les PopPK, QSP et PK\/PD, extrapolation p\u00e9diatrique, strat\u00e9gie de mod\u00e9lisation et pr\u00e9paration des interactions r\u00e9glementaires.<\/p>\r\n    <div class=\"mrd-cta-buttons\">\r\n      <a href=\"\/fr\/midd\/\" class=\"mrd-btn primary\">D\u00e9couvrir nos expertises<\/a>\r\n      <a href=\"\/fr\/contact\/\" class=\"mrd-btn ghost\">Nous contacter<\/a>\r\n    <\/div>\r\n  <\/section>\r\n\r\n  <!-- R\u00c9F\u00c9RENCES -->\r\n  <section class=\"mrd-section\">\r\n    <span class=\"mrd-kicker\">R\u00e9f\u00e9rences<\/span>\r\n    <div class=\"mrd-refs\">\r\n      <ol>\r\n        <li>U.S. Food and Drug Administration (FDA). (2023). <em>Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases.<\/em> Guidance for Industry.<\/li>\r\n        <li>Chen, E. P. (2025). Integrated PK\/PD Approaches to Human Dose Prediction. In <em>Putting Pharmacokinetics and Pharmacodynamics to Work in Drug Discovery<\/em>, E. P. Chen (Ed.). <a href=\"https:\/\/doi.org\/10.1002\/9781119650263.ch17\" target=\"_blank\" rel=\"noopener\">doi.org\/10.1002\/9781119650263.ch17<\/a><\/li>\r\n        <li>International Council for Harmonisation (ICH). (2026). <em>ICH M15 General Principles for Model-Informed Drug Development.<\/em><\/li>\r\n        <li>ICH. <em>Guideline E11A on pediatric extrapolation.<\/em> <a href=\"https:\/\/www.ema.europa.eu\/system\/files\/documents\/scientific-guideline\/ich-guideline-e11a-pediatric-extrapolation-step-5_en.pdf\" target=\"_blank\" rel=\"noopener\">ema.europa.eu<\/a><\/li>\r\n        <li>U.S. Food and Drug Administration (FDA). (2023). <em>Model-Informed Drug Development Paired Meeting Program.<\/em><\/li>\r\n        <li>Ribba, B., et al. (2014). A review of mixed-effects models of tumor growth and anticancer drug effects. <em>CPT: Pharmacometrics &amp; Systems Pharmacology<\/em>, 3(5), 113.<\/li>\r\n        <li>Peck, R. W., Shahin, M. H., &amp; Vinks, A. A. (2021). Precision Dosing: The Clinical Pharmacology of Goldilocks. <em>Clinical Pharmacology &amp; Therapeutics<\/em>, 109, 11-14. <a href=\"https:\/\/doi.org\/10.1002\/cpt.2112\" target=\"_blank\" rel=\"noopener\">doi.org\/10.1002\/cpt.2112<\/a><\/li>\r\n      <\/ol>\r\n    <\/div>\r\n  <\/section>\r\n\r\n<\/div>\r\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>",
        "protected": false
    },
    "excerpt": {
        "rendered": "<p>Dans les maladies rares, les cadres statistiques traditionnels atteignent vite leurs limites : les effectifs manquent, les donn\u00e9es cliniques sont clairsem\u00e9es. Le MIDD devient alors la voie permettant de transformer des signaux \u00e9pars en une d\u00e9monstration m\u00e9canistiquement solide.<\/p>",
        "protected": false
    },
    "author": 2,
    "featured_media": 5302,
    "comment_status": "closed",
    "ping_status": "closed",
    "sticky": false,
    "template": "elementor_header_footer",
    "format": "standard",
    "meta": {
        "_acf_changed": false,
        "footnotes": ""
    },
    "categories": [
        39,
        41
    ],
    "tags": [],
    "service-associe": [],
    "class_list": [
        "post-5295",
        "post",
        "type-post",
        "status-publish",
        "format-standard",
        "has-post-thumbnail",
        "hentry",
        "category-a-la-une",
        "category-expertise"
    ],
    "acf": [],
    "yoast_head": "<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Le r\u00f4le du MIDD dans le d\u00e9veloppement de m\u00e9dicaments pour les maladies rares\u00a0 - PhinC Group<\/title>\n<meta name=\"description\" content=\"Maladies rares : comment le MIDD transforme des donn\u00e9es cliniques rares en preuves r\u00e9glementaires. PopPK, QSP, PK\/PD et extrapolation p\u00e9diatrique.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.phinc-group.com\/fr\/midd-for-rare-diseases-therapies\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Le r\u00f4le du MIDD dans le d\u00e9veloppement de m\u00e9dicaments pour les maladies rares\u00a0 - PhinC Group\" \/>\n<meta property=\"og:description\" content=\"Maladies rares : comment le MIDD transforme des donn\u00e9es cliniques rares en preuves r\u00e9glementaires. PopPK, QSP, PK\/PD et extrapolation p\u00e9diatrique.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.phinc-group.com\/fr\/midd-for-rare-diseases-therapies\/\" \/>\n<meta property=\"og:site_name\" content=\"PhinC Group\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-30T08:49:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-02T10:08:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/10\/Examen-medical-dans-une-clinique-de-campagne.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Mohamed Taourirt\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mohamed Taourirt\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/midd-for-rare-diseases-therapies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/midd-for-rare-diseases-therapies\\\/\"},\"author\":{\"name\":\"Mohamed Taourirt\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/person\\\/4c52ff6996589ff3ca1ec2882fc5dd0a\"},\"headline\":\"Le r\u00f4le du MIDD dans le d\u00e9veloppement de m\u00e9dicaments pour les maladies rares\u00a0\",\"datePublished\":\"2026-10-30T08:49:51+00:00\",\"dateModified\":\"2026-11-02T10:08:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/midd-for-rare-diseases-therapies\\\/\"},\"wordCount\":1132,\"publisher\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/midd-for-rare-diseases-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Examen-medical-dans-une-clinique-de-campagne.png\",\"articleSection\":[\"A la une\",\"Expertise\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/midd-for-rare-diseases-therapies\\\/\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/midd-for-rare-diseases-therapies\\\/\",\"name\":\"Le r\u00f4le du MIDD dans le d\u00e9veloppement de m\u00e9dicaments pour les maladies rares\u00a0 - PhinC Group\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/midd-for-rare-diseases-therapies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/midd-for-rare-diseases-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Examen-medical-dans-une-clinique-de-campagne.png\",\"datePublished\":\"2026-10-30T08:49:51+00:00\",\"dateModified\":\"2026-11-02T10:08:57+00:00\",\"description\":\"Maladies rares : comment le MIDD transforme des donn\u00e9es cliniques rares en preuves r\u00e9glementaires. PopPK, QSP, PK\\\/PD et extrapolation p\u00e9diatrique.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/midd-for-rare-diseases-therapies\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.phinc-group.com\\\/midd-for-rare-diseases-therapies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/midd-for-rare-diseases-therapies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Examen-medical-dans-une-clinique-de-campagne.png\",\"contentUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Examen-medical-dans-une-clinique-de-campagne.png\",\"width\":1672,\"height\":941},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/midd-for-rare-diseases-therapies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.phinc-group.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Le r\u00f4le du MIDD dans le d\u00e9veloppement de m\u00e9dicaments pour les maladies rares\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/\",\"name\":\"PhinC Group\",\"description\":\"Quantitative Pharmacology Solutions &amp; Modeling\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#organization\",\"name\":\"PhinC Group\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Icone-PhinC-New_white-600px.jpg\",\"contentUrl\":\"https:\\\/\\\/www.phinc-group.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Icone-PhinC-New_white-600px.jpg\",\"width\":600,\"height\":600,\"caption\":\"PhinC Group\"},\"image\":{\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/#\\\/schema\\\/person\\\/4c52ff6996589ff3ca1ec2882fc5dd0a\",\"name\":\"Mohamed Taourirt\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g\",\"caption\":\"Mohamed Taourirt\"},\"url\":\"https:\\\/\\\/www.phinc-group.com\\\/fr\\\/author\\\/mtaourirt\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->",
    "yoast_head_json": {
        "title": "Le r\u00f4le du MIDD dans le d\u00e9veloppement de m\u00e9dicaments pour les maladies rares\u00a0 - PhinC Group",
        "description": "Maladies rares : comment le MIDD transforme des donn\u00e9es cliniques rares en preuves r\u00e9glementaires. PopPK, QSP, PK\/PD et extrapolation p\u00e9diatrique.",
        "robots": {
            "index": "index",
            "follow": "follow",
            "max-snippet": "max-snippet:-1",
            "max-image-preview": "max-image-preview:large",
            "max-video-preview": "max-video-preview:-1"
        },
        "canonical": "https:\/\/www.phinc-group.com\/fr\/midd-for-rare-diseases-therapies\/",
        "og_locale": "fr_FR",
        "og_type": "article",
        "og_title": "Le r\u00f4le du MIDD dans le d\u00e9veloppement de m\u00e9dicaments pour les maladies rares\u00a0 - PhinC Group",
        "og_description": "Maladies rares : comment le MIDD transforme des donn\u00e9es cliniques rares en preuves r\u00e9glementaires. PopPK, QSP, PK\/PD et extrapolation p\u00e9diatrique.",
        "og_url": "https:\/\/www.phinc-group.com\/fr\/midd-for-rare-diseases-therapies\/",
        "og_site_name": "PhinC Group",
        "article_published_time": "2026-10-30T08:49:51+00:00",
        "article_modified_time": "2026-11-02T10:08:57+00:00",
        "og_image": [
            {
                "width": 1672,
                "height": 941,
                "url": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/10\/Examen-medical-dans-une-clinique-de-campagne.png",
                "type": "image\/png"
            }
        ],
        "author": "Mohamed Taourirt",
        "twitter_card": "summary_large_image",
        "twitter_misc": {
            "\u00c9crit par": "Mohamed Taourirt",
            "Dur\u00e9e de lecture estim\u00e9e": "6 minutes"
        },
        "schema": {
            "@context": "https:\/\/schema.org",
            "@graph": [
                {
                    "@type": "Article",
                    "@id": "https:\/\/www.phinc-group.com\/midd-for-rare-diseases-therapies\/#article",
                    "isPartOf": {
                        "@id": "https:\/\/www.phinc-group.com\/midd-for-rare-diseases-therapies\/"
                    },
                    "author": {
                        "name": "Mohamed Taourirt",
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#\/schema\/person\/4c52ff6996589ff3ca1ec2882fc5dd0a"
                    },
                    "headline": "Le r\u00f4le du MIDD dans le d\u00e9veloppement de m\u00e9dicaments pour les maladies rares\u00a0",
                    "datePublished": "2026-10-30T08:49:51+00:00",
                    "dateModified": "2026-11-02T10:08:57+00:00",
                    "mainEntityOfPage": {
                        "@id": "https:\/\/www.phinc-group.com\/midd-for-rare-diseases-therapies\/"
                    },
                    "wordCount": 1132,
                    "publisher": {
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#organization"
                    },
                    "image": {
                        "@id": "https:\/\/www.phinc-group.com\/midd-for-rare-diseases-therapies\/#primaryimage"
                    },
                    "thumbnailUrl": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/10\/Examen-medical-dans-une-clinique-de-campagne.png",
                    "articleSection": [
                        "A la une",
                        "Expertise"
                    ],
                    "inLanguage": "fr-FR"
                },
                {
                    "@type": "WebPage",
                    "@id": "https:\/\/www.phinc-group.com\/midd-for-rare-diseases-therapies\/",
                    "url": "https:\/\/www.phinc-group.com\/midd-for-rare-diseases-therapies\/",
                    "name": "Le r\u00f4le du MIDD dans le d\u00e9veloppement de m\u00e9dicaments pour les maladies rares\u00a0 - PhinC Group",
                    "isPartOf": {
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#website"
                    },
                    "primaryImageOfPage": {
                        "@id": "https:\/\/www.phinc-group.com\/midd-for-rare-diseases-therapies\/#primaryimage"
                    },
                    "image": {
                        "@id": "https:\/\/www.phinc-group.com\/midd-for-rare-diseases-therapies\/#primaryimage"
                    },
                    "thumbnailUrl": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/10\/Examen-medical-dans-une-clinique-de-campagne.png",
                    "datePublished": "2026-10-30T08:49:51+00:00",
                    "dateModified": "2026-11-02T10:08:57+00:00",
                    "description": "Maladies rares : comment le MIDD transforme des donn\u00e9es cliniques rares en preuves r\u00e9glementaires. PopPK, QSP, PK\/PD et extrapolation p\u00e9diatrique.",
                    "breadcrumb": {
                        "@id": "https:\/\/www.phinc-group.com\/midd-for-rare-diseases-therapies\/#breadcrumb"
                    },
                    "inLanguage": "fr-FR",
                    "potentialAction": [
                        {
                            "@type": "ReadAction",
                            "target": [
                                "https:\/\/www.phinc-group.com\/midd-for-rare-diseases-therapies\/"
                            ]
                        }
                    ]
                },
                {
                    "@type": "ImageObject",
                    "inLanguage": "fr-FR",
                    "@id": "https:\/\/www.phinc-group.com\/midd-for-rare-diseases-therapies\/#primaryimage",
                    "url": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/10\/Examen-medical-dans-une-clinique-de-campagne.png",
                    "contentUrl": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2026\/10\/Examen-medical-dans-une-clinique-de-campagne.png",
                    "width": 1672,
                    "height": 941
                },
                {
                    "@type": "BreadcrumbList",
                    "@id": "https:\/\/www.phinc-group.com\/midd-for-rare-diseases-therapies\/#breadcrumb",
                    "itemListElement": [
                        {
                            "@type": "ListItem",
                            "position": 1,
                            "name": "Accueil",
                            "item": "https:\/\/www.phinc-group.com\/en\/"
                        },
                        {
                            "@type": "ListItem",
                            "position": 2,
                            "name": "Le r\u00f4le du MIDD dans le d\u00e9veloppement de m\u00e9dicaments pour les maladies rares\u00a0"
                        }
                    ]
                },
                {
                    "@type": "WebSite",
                    "@id": "https:\/\/www.phinc-group.com\/fr\/#website",
                    "url": "https:\/\/www.phinc-group.com\/fr\/",
                    "name": "PhinC Group",
                    "description": "Quantitative Pharmacology Solutions &amp; Modeling",
                    "publisher": {
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#organization"
                    },
                    "potentialAction": [
                        {
                            "@type": "SearchAction",
                            "target": {
                                "@type": "EntryPoint",
                                "urlTemplate": "https:\/\/www.phinc-group.com\/fr\/?s={search_term_string}"
                            },
                            "query-input": {
                                "@type": "PropertyValueSpecification",
                                "valueRequired": true,
                                "valueName": "search_term_string"
                            }
                        }
                    ],
                    "inLanguage": "fr-FR"
                },
                {
                    "@type": "Organization",
                    "@id": "https:\/\/www.phinc-group.com\/fr\/#organization",
                    "name": "PhinC Group",
                    "url": "https:\/\/www.phinc-group.com\/fr\/",
                    "logo": {
                        "@type": "ImageObject",
                        "inLanguage": "fr-FR",
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#\/schema\/logo\/image\/",
                        "url": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/01\/Icone-PhinC-New_white-600px.jpg",
                        "contentUrl": "https:\/\/www.phinc-group.com\/wp-content\/uploads\/2025\/01\/Icone-PhinC-New_white-600px.jpg",
                        "width": 600,
                        "height": 600,
                        "caption": "PhinC Group"
                    },
                    "image": {
                        "@id": "https:\/\/www.phinc-group.com\/fr\/#\/schema\/logo\/image\/"
                    }
                },
                {
                    "@type": "Person",
                    "@id": "https:\/\/www.phinc-group.com\/fr\/#\/schema\/person\/4c52ff6996589ff3ca1ec2882fc5dd0a",
                    "name": "Mohamed Taourirt",
                    "image": {
                        "@type": "ImageObject",
                        "inLanguage": "fr-FR",
                        "@id": "https:\/\/secure.gravatar.com\/avatar\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g",
                        "url": "https:\/\/secure.gravatar.com\/avatar\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g",
                        "contentUrl": "https:\/\/secure.gravatar.com\/avatar\/fb6e28f32440aa3a88b3657037d3180a08ec0bd3b98a8c4e463d059c0af8bd42?s=96&d=mm&r=g",
                        "caption": "Mohamed Taourirt"
                    },
                    "url": "https:\/\/www.phinc-group.com\/fr\/author\/mtaourirt\/"
                }
            ]
        }
    },
    "_links": {
        "self": [
            {
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/posts\/5295",
                "targetHints": {
                    "allow": [
                        "GET"
                    ]
                }
            }
        ],
        "collection": [
            {
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/posts"
            }
        ],
        "about": [
            {
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/types\/post"
            }
        ],
        "author": [
            {
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/users\/2"
            }
        ],
        "replies": [
            {
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/comments?post=5295"
            }
        ],
        "version-history": [
            {
                "count": 9,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/posts\/5295\/revisions"
            }
        ],
        "predecessor-version": [
            {
                "id": 5307,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/posts\/5295\/revisions\/5307"
            }
        ],
        "wp:featuredmedia": [
            {
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/media\/5302"
            }
        ],
        "wp:attachment": [
            {
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/media?parent=5295"
            }
        ],
        "wp:term": [
            {
                "taxonomy": "category",
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/categories?post=5295"
            },
            {
                "taxonomy": "post_tag",
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/tags?post=5295"
            },
            {
                "taxonomy": "service-associe",
                "embeddable": true,
                "href": "https:\/\/www.phinc-group.com\/fr\/wp-json\/wp\/v2\/service-associe?post=5295"
            }
        ],
        "curies": [
            {
                "name": "wp",
                "href": "https:\/\/api.w.org\/{rel}",
                "templated": true
            }
        ]
    }
}